TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01045213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Care
Description: Study looking at the efficacy of a combination of Guideline-based COPD education, self-management training, remote telemonitoring and enhanced communication with a coordinator.
Study: NCT02516553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894999
Description: film-coated tablets
Study: NCT00459121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zactima
Description: Zactima- 100 mg orally daily, starting on day 1 of cycle 1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Neoadjuvant surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.
Study: NCT03612557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: penicillin G benzathine
Description: 2.4 million units (IM) of benzathine benzylpenicillin
Study: NCT00870597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multifocal IOL implantation + Vitrectomy
Description: 25-gauge transconjuntival sutureless vitrectomy (TSV)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multifocal IOL implantation - Vitrectomy
Description: Multifocal IOL implantation without transconjunctival vitrectomy
Study: NCT02205983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg hydromorphone
Description: We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
Study: NCT03514238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Sitting Condition (C)
Description: Blood draws matched for exercise time will be taken while participant remains seated for 35 minutes (0min, 7min, 14min, 21min, 28min, 35min).
Study: NCT02205983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000 mg Acetaminophen
Description: We are administering sublingual buprenorphine to healthy volunteers to measure its effects on the performance of a verbal task.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg hydromorphone
Description: We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dextrose
Description: We are administering dextrose to healthy volunteers for our placebo group.
Study: NCT00822796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermogard™
Description: Those who have a Thermogard™ central venous warming catheter placed prior to surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard central venous catheter
Description: Those who have a standard central venous catheter placed prior to surgery
Study: NCT02029586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB12066 200mg
Description: oral administration, 100mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration, 100mg bid
Study: NCT01260519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: unfractionated heparin 2000 unites
Study: NCT06160570

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Modulated Radiation Therapy
Description: Radiotherapy technique: IMRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimension Conformal Radiation Therapy
Description: Radiotherapy technique: 3DCRT
Study: NCT04106167

Intervention type: GENETIC
Intervention: Allogeneic natural killer (NK) cell
Description: No study drug is administered in this study. Subjects who received an allogeneic, iPSC-derived NK cell in a previous trial will be evaluated in this trial for long-term safety and efficacy
Study: NCT03858543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-L Lactic Acid
Description: After initial treatment, reassessment will be conducted at 3 follow-up visits. Photographs will be taken for blinded evaluators to compare post-treatment to the original pre-treatment photographs. At final visit, a questionnaire will be administered to rate treatment satisfaction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional laser treatment
Description: After initial treatment, reassessment will be conducted at 3 follow-up visits. Photographs will be taken for blinded evaluators to compare post-treatment to the original pre-treatment photographs. At final visit, a questionnaire will be administered to rate treatment satisfaction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional laser treatment
Description: After initial treatment, reassessment will be conducted at 3 follow-up visits. Photographs will be taken for blinded evaluators to compare post-treatment to the original pre-treatment photographs. At final visit, a questionnaire will be administered to rate treatment satisfaction.
Study: NCT02117700

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine 600 mg once/day
Description: NAC 600 mg once/day + Placebo once/day for 16 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine 600mg twice/day
Description: N-acetyl cysteine 600 mg twice/day for 16 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo twice/day
Description: Placebo capsules twice/day for 16 weeks
Study: NCT01920607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic anal sphincter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sacral nerve stimulation
Study: NCT02228772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN 9708
Description: Patients will received standard chemotherapy as well as MLN 9708 in escalating doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Standard chemotherapy dosage and duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Standard chemotherapy dosage and duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Standard chemotherapy dosage and duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Standard chemotherapy dosage and duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Standard chemotherapy dosage and duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Standard chemotherapy dosage and duration
Study: NCT01589263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: onaBoNT-A + placebo
Description: 200 U prostate injection once~Arms: ARM 1: onaBoNT-A + placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: onaBoNT-A + placebo
Description: 200 U prostate injection once~Arms: ARM 1: onaBoNT-A + placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin + placebo
Description: 0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin + placebo
Description: 0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin
Study: NCT03793283

Intervention type: DEVICE
Intervention: CSII
Description: Currently receiving CSII therapy during 6 or more months.
Study: NCT03993444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: communication and problem solving
Description: a program for supervisors and employees including skills training, validating communication, problem solving

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducation
Description: lecture/course for supervisors and employees on risk factors and actions for people experiencing stress and/or pain
Study: NCT03611881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: 4 or 8 weeks of behavioral counseling support to promote smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: 4 or 8 weeks of behavioral counseling support to promote smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: 4 or 8 weeks of behavioral counseling support to promote smoking cessation.
Study: NCT01659086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose of saline placebo administered intramuscularly (IM) in deltoid region of arm.
Study: NCT03611881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: 4 or 8 weeks of behavioral counseling support to promote smoking cessation.
Study: NCT03793283

Intervention type: DRUG
Intervention: Multiple dose insulin injections
Description: Currently receiving MDI therapy during 6 or more months.
Study: NCT01714713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124
Description: Arm 1, 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124
Description: Arm 1, 2
Study: NCT01136746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human regular insulin
Description: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
Study: NCT03362203

Intervention type: OTHER
Intervention: Patients with chronic neck pain
Description: Patients,aged 21-80 years, must have experienced neck pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.

Intervention type: OTHER
Intervention: Subjects without chronic neck pain
Description: Subjects,aged 21-80 years, must not have presented episodes of chronic neck pain for more than 7 days in the last 12 months.
Study: NCT01983618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene nerve block and catheter

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Interscalene catheter
Study: NCT00756093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Ultra Lubricant Eye Drops
Description: Systane Ultra Lubricant Eye Drops one drop each eye one time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optive Lubricant Eye Drops
Description: Optive Lubricant Eye Drops one drop each eye one time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blink Tears
Description: Blink Tears one drop each eye one time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GenTeal Moderate Lubricant Eye Drops
Description: GenTeal Moderate Lubricant Eye Drops one drop each eye one time
Study: NCT00662389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apsara Thermal Wand System
Description: Single radiofrequency cycle to dermal tissue
Study: NCT04269941

Intervention type: OTHER
Intervention: total or subtotal gastrectomy
Description: resection of the gastric tumor
Study: NCT03291730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing and journaling exercise
Description: May help reduce anxiety of receiving chemotherapy
Study: NCT00973180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Label
Description: A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
Study: NCT02802072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterprise stent implantation
Description: Enterprise stent system (Johnson \& Johnson (Shanghai) Medical Equipment Co.,Ltd., China) is a closed loop self-expanding stent system that is made of Ni-Ti alloy. It consists of a self-expanding stent and a delivery system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Only aspirin medication
Description: Only aspirin medication will be conducted, initial dose is 300 mg/d, 200 mg/d 6 months later, and 100 mg/d 1 year later.
Study: NCT00719524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMBRABULIN (AVE8062)
Description: Dose escalation study with combination chemotherapy
Study: NCT03907969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7648
Description: Core: AZD7648 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7648
Description: Core: AZD7648 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Description: The starting dose of PLD is 40 mg/m\^2, administered by intravenous infusion once every 4 weeks, for a maximum of 6 cycles
Study: NCT01659086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose of saline placebo administered intramuscularly (IM) in deltoid region of arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 dose of saline placebo administered intramuscularly (IM) in deltoid region of arm.
Study: NCT03611881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: 4 or 8 weeks of behavioral counseling support to promote smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: 4 or 8 weeks of behavioral counseling support to promote smoking cessation.
Study: NCT03642028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant, a dual orexin receptor antagonist, is the first in a new class of drugs with great promise of addressing insomnia in Veterans with PTSD. Suvorexant targets the orexin neuropeptide system and has been shown to be highly successful in treating insomnia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.
Study: NCT01632176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief, motivational interview and one booster session
Description: This is a one session brief motivational interview-style intervention that follows a 9-step intervention algorithm. The intervention is delivered by a trained motivational interview interventionist. There is one booster call 10 days after the intervention/
Study: NCT00987636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: intravenously at 28 day intervals beginning with cycle 6 of VAC/VAI consolidation chemotherapy for a total period of nine months.~Patients \< 18 years will receive 0.05 mg/kg BW by IV infusion 30 min-1 h.~Patients \>= 18 years will receive a bodyweight-dependent dose:~Patients \>40kg receive 4 mg by IV infusion 30 min-1h Patients 20-40 kg receive 2 mg by IV infusion 30 min-1h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: intravenously, day -6 to d -3 adults: 0.8 mg/kg body weight (BW) children and adolescents: \<9 kg= 1mg/kg BW 9 - \<16 kg= 1.2 mg/kg BW 16 - 23 kg= 1.1 mg/kg BW \>23 - 34 kg= 0.95 mg/kg BW \>34 kg = 0.8 mg/kg BW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: 12 g/m² d-5 to d-3
Study: NCT01216904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch
Description: 7 mg patches to be worn for 16 hours per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo patch to be worn 16 hours per day
Study: NCT02368951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1187982
Description: A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the starting dose based on toxicology data. The investigational drug will be administered as a 1-hour IV infusion once every 21 days at the trial site (Day 1 of each 21-day Cycle). The maximum possible dose escalation will be 2-fold and not more than 0.5 mg/kg BW until maximum tolerated dose is selected
Study: NCT00106249

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Stimulus train of 30 min duration, 1Hz frequency, and 110% of the motor threshold intensity given once a day, 5 days a week, for 4 weeks by Magstim SuperRapid Magnetic Stimulator.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham rTMS will be administered using the Magstim Sham coil which contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (less than 3%) magnetic field is delivered to the cortex in order to provoke a subjective sensation similar to that obtained with the real stimulation but without inducing significant cortical stimulation.
Study: NCT03639922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib 400mg
Description: 2 tablets of Imatinib 400mg per day for 6 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 2 tablets of placebo per day for 6 days
Study: NCT03373318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human albumin
Description: Single dose as a primer for the CEC, in sufficient quantity to reach a concentration of 4% of the total volume of priming.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasmalyte
Description: The dose and the speed of administration depend on the age, weight, clinical and biological status of the patient and the concomitant treatment. The recommended dose for adults, the elderly and adolescents: from 500 ml to 3 liters / 24 hours.
Study: NCT03162094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVX012 Ophthalmic Solution Low dose
Description: Ocular topical administration of AVX Ophthalmic Solution Low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVX012 Ophthalmic Solution High dose
Description: Ocular topical administration of AVX Ophthalmic Solution High dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle)
Description: Ocular topical administration of placebo (vehicle Ophthalmic Solution)
Study: NCT04472819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2285 tablet
Description: single dose or multi-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2285 tablet
Description: single dose or multi-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2285 tablet
Description: single dose or multi-dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose or multi-dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose or multi-dose
Study: NCT05806619

Intervention type: OTHER
Intervention: histopathological analysis; morphological and non-morphological magnetic resonance
Description: The surgical material removed during surgery was subjected to histological analysis. Morphological and non-morphological magnetic resonance examination before the neurosurgical surgery, according to clinical practice.
Study: NCT04472819

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose or multi-dose
Study: NCT03945656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin icodec
Description: Participants will receive subcutaneous (s.c.) injections of insulin 287 OW for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin icodec
Description: Participants will receive subcutaneous (s.c.) injections of insulin 287 OW for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Participants will receive daily s.c. injections of insulin glargine U100 for 12 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Participants will receive daily s.c. injections of insulin glargine U100 for 12 days
Study: NCT03021044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity intervention
Description: 30, 60, 90 and 120 days after hospital discharge a clinical visit and session of physical activity training and program

Intervention type: OTHER
Group type: OTHER
Intervention: standard of care
Description: 30, 60, 90 and 120 days after hospital discharge a clinical visit with correct style life recommendation
Study: NCT04391088

Intervention type: OTHER
Intervention: vaccine coverage assessment
Description: vaccine coverage assessment